Objective Promoter single-nucleotide polymorphisms (SNPs) of the ABCB1 gene, encoding the placental efflux transporter P-glycoprotein, can affect its expression and alter xenobiotic transfer from the maternal to the fetal circulation. Because SNPs are arranged in specific combinations as defined haplotypes, the aims of this study were to: (i) determine the placental haplotype structure of the ABCB1 promoter and (ii) determine the differential effect of these haplotypes on placental ABCB1 promoter activity.
Introduction
The growing use of medications during pregnancy [1] emphasizes the need for maximizing therapy for the mother while minimizing risks to her fetus. Further understanding of the mechanisms regulating drug transfer across the placenta is an important step toward this goal. Placental efflux transporters regulate drug transfer from the maternal to the fetal circulation. P-glycoprotein (P-gp), encoded by the ABCB1 (MDR1) gene, is an important placental efflux transporter highly expressed in trophoblasts [2] that interacts with many compounds [3] . It actively extrudes its substrates from the trophoblasts back into the maternal circulation, thus limiting fetal exposure [4] . Therefore, variability in placental P-gp expression/activity poses a challenge to physicians treating pregnant women as it can significantly influence maternal and fetal exposure to prescribed medications.
Hemauer et al. [5] and others [6, 7] demonstrated interindividual variability in placental P-gp expression/activity. Though the underlying mechanisms are not well understood, such variability could largely be due to single-nucleotide polymorphisms (SNPs) of the ABCB1 gene, which could affect P-gp expression/function. A few ABCB1 coding region SNPs (C1236T, rs1128503; C3435T, rs1045642, and G2677T/A, rs2032582) have been evaluated for their effect on P-gp expression/function. However, there is considerable discrepancy in the results, where increased, decreased, and nonsignificant effects have been reported [6] [7] [8] [9] [10] [11] [12] [13] [14] . Besides coding SNPs, other SNPs in the ABCB1 promoter could alter P-gp expression by affecting ABCB1 transcription. A few studies evaluated some of these SNPs individually but conflicting data were also reported [7, [15] [16] [17] [18] [19] .
The controversial results are not surprising as SNPs are not arrayed individually, but rather form defined combinations or haplotypes with varying degrees of linkage disequilibrium. Thus, several SNPs, creating specific haplotypes, act in concert to provide the observed variability in response to Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.pharmacogeneticsandgenomics.com.
an exposure. Recently, we reported the phenotypic effect of a SNP is not always consistent and varies depending on its presence within a specific haplotype [20, 21] . Therefore, genotyping of a single or a few individual SNPs may fail to capture true functionality of genetic variants.
The haplotype structure of the ABCB1 promoter is currently unknown, and their functional and biological significance remain elusive. We therefore comprehensively identified SNPs of the ABCB1 promoter and determined the haplotype structure encompassing them. We then determined the effect of the haplotypes on ABCB1 promoter activity. Our hypothesis is that promoter haplotypes, rather than individual SNPs, differentially alter ABCB1 promoter activity and thus affect placental P-gp expression.
Materials and methods

Placenta collection
Term placentas (38-41 weeks) were collected from 100 volunteers upon delivery in the Obstetrics and Gynecology Department at University of Texas Medical Branch (UTMB) by research nurses according to a protocol approved by the UTMB Institutional Review Board (IRB #02-106). Volunteers were recruited without regard to age or race/ ethnicity and signed a written informed consent form. Placentas collected were transported to our laboratory along with a deidentified data sheet with information on maternal age, self-reported race/ethnicity, health conditions (if any), current medications, gestational age, and type of delivery. Placentas were excluded if there were pregnancy complications, preterm delivery, documented drug abuse during pregnancy, intake of medications that are known P-gp substrates, or infection with HIV or hepatitis. DNA was isolated for ABCB1 promoter amplification via PCR from a 100 mg tissue section obtained from the fetal side of each placenta using the Qiagen DNeasy Blood & Tissue kit (Qiagen Inc., Valencia, California, USA).
ABCB1 promoter PCR amplification and singlenucleotide polymorphism determination
The proximal ABCB1 promoter was PCR-amplified using primers encompassing a 2050 bp sequence upstream and 300 bp downstream of the transcription start site, respectively [22] . PCR conditions were 95°C (20 s), annealing at 63°C (30 s), and extension at 68°C (50 s). Amplicons were purified using a QIAquick PCR Purification Kit (Qiagen Inc.). Four sets of primers were designed (see Supplementary Table S1 , Supplemental digital content 1, http://links.lww.com/FPC/B302) for DNA sequencing on an ABI Prism 3130XL sequencer (ABI Prism is Applied Biosystems, Foster City, California, USA) at the UTMB Molecular Genomics Core Facility. Sequences were assembled into contigs using DNA Baser version 4.16 (Heracle Biosoft S.R.L, Pite¸sti, Romania) as previously described [20] . Variants were determined using mixed-base calling with the Mutation Detection module of the DNA Baser software (Heracle Biosoft S.R.L, Piteşti, Romania). The detection settings were: SNP scanning: 50, peak-area ratios: 30% and peak overlap: 50%. All called SNPs were manually verified, and complete sequences were manually verified for any noncalled SNPs.
Haplotype inference
SNPs were identified by comparing the generated sequences to the reference ABCB1 promoter sequence (Entrez GeneID: 5243, GenBank accession NT_007933) using DNA Baser. Composite genotypes were used to infer haplotypes by Bayesian statistics implemented in PHASE (PHylogenetic And Sequence Evolution; http:// c4c.uwc4c.com/expresslicensetechnologies/phase). Haplotype pairs were assigned to each placenta and their frequencies were determined.
ABCB1 promoter haplotypes luciferase reporter construct generation
To investigate the differential haplotype effects on ABCB1 promoter activity, 16 reporter constructs were generated. These represented 14 haplotypes that were found in our population (see the Results section) in addition to two constructs we generated to assist in evaluating the effect of genetic variants on promoter activity.
To generate vectors containing the different haplotypes, PCR-amplified ABCB1 promoter haplotypes were double digested with the restriction enzymes KpnI-HF and NheI-HF (New England Biolabs, Ipswitch, Massachusetts, USA) and ligated into a NanoLuc Luciferase pNL1.1 vector (Promega, Madison, Wisconsin, USA). Then, 5α E. coli (New England Biolabs) were transformed with the generated reporters and plated on 100 μg/ml ampicillin LB agar plates. Colonies were grown in LB broth with 100 μg/ml ampicillin for 18-24 h. Plasmids were isolated using the endotoxin-free ZR Plasmid Miniprep -Classic kit (Zymo Research Corp., Irvine, California, USA) and quantified at 260 nm using a DS-11 spectrophotometer (DeNovix Inc., Wilmington, Delaware, USA). Plasmids were then sequenced to verify the haplotype. Isolated plasmids were stored at − 20°C until transfection into human 3A trophoblast cells (CRL-1584; American Type Culture Collection, Manassas, Virginia, USA). The effect of the haplotypes on ABCB1 promoter activity in 3A cells was determined using the manufacturer's protocol for the NanoGlo Dual-Luciferase Assay System (Promega).
Site-directed mutagenesis
To elucidate the effects of specific SNPs found in ABCB1 haplotypes expressing increased and decreased activity, we utilized the QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, California, USA). Site-Directed mutagenesis primers were designed according to the manufacturer's protocol, and utilizing the QuikChange Primer Design Tool (http://www.genomics.agilent.com). Mutant synthesis was performed with 100 ng double-stranded promoter DNA in the pNL1.1 plasmid with an extension time of 3 min. Plasmids were then restriction-digested with DpnI for 30 min to remove template DNA. Then, 5α E. coli were transformed with the DNA as described above. Mutant colonies were confirmed by DNA sequence analysis.
Cell culture and haplotype constructs transfection
Human 3A placental cells were used as the host for haplotype construct transfection. Cells were maintained in 75 cm 2 flasks with minimal essential medium with Earle's salts and L-glutamine (Gibco, Grand Island, New York, USA) supplemented with 10% fetal bovine serum in 5% CO 2 at 37°C. Cells were passaged at less than or equal to 85% confluency and subcultured at a 3 : 1 ratio. A solution of trypsin-EDTA was used to detach the cells for subculture or transfer to six-well plates for transfection. Transfections were performed between passages 6-8 with cells at low confluency (≤ 40%) with 2 μl Fugene 6 (Promega), 0.6 μg promoter haplotype plasmid DNA, and 0.06 μg of the constitutively active firefly luciferase plasmid pGL4.53 PGK (Promega), which was used for in-well normalization of transfection efficiency. Transfection efficiency for 3A cells was determined using a green fluorescent protein plasmid (AcGFP1-C1) under these same transfection conditions. Cells were allowed to recover for 36-48 h before harvest.
NanoGlo Dual-Luciferase Assay for determination of the effect of the different haplotypes on ABCB1 promoter activity
The NanoGlo Dual-Luciferase Reporter Assay (Promega) was performed according to the manufacturer's protocol. Briefly, 3A cells were harvested using passive lysis buffer 36-48 h after transfection. Luciferase activity was determined by chemiluminescence in triplicate using a Tecan GenIOS Pro (Tecan, Durham, North Carolina, USA). To account for variability in transfection efficiency, Nanoluciferase luminescence was normalized in-well against a cotransfected firefly luciferase. Each experiment was repeated at least three times.
In-silico analysis of the ABCB1 promoter region
The putative transcription factor (TF) binding site predictor PROMO (ALGGEN Research Software, http:// alggen.lsi.upc.edu) [23, 24] was used for in-silico confirmation of reported cis-binding elements [15] and to predict potential TF binding sites within the ABCB1 promoter region. A map of the proximal promoter sequence with the identified SNPs with known and predicted binding sites was generated (see the Results section).
Statistical analysis
Genotype frequencies for each SNP were estimated from our 100 placenta samples and tested for deviation from Hardy-Weinberg equilibrium (HWE) by χ 2 and permutation tests, both implemented in the linkage disequilibrium analyzer, version 1.0 program [25] . Deviations from HWE were considered significant at P value less than 0.05 for either test. None of the SNPs identified deviated from HWE. Frequencies of haplotypes inferred from the PHASE analysis were used to determine haplotype frequencies. A Kruskal-Wallis one-way analysis of variance was used to compare luminescence values corresponding to the different haplotypes to determine their effect on ABCB1 promoter activity. Post-hoc analysis using Dunn's method was used to compare the luminescence values for the individual haplotypes against the ancestral haplotype. P values less than 0.05 were considered significant.
Results
ABCB1 promoter single-nucleotide polymorphisms and haplotype inference
In our study population, we identified a total of 12 out of 23 SNPs reported by the 1000 Genome Project [26] ( Table 1) . These SNPs had minor allele frequencies ranging from 5% for the most frequent SNP (T-1017aC) to 0.5% for the least frequent SNPs. Some SNPs occurred at frequencies comparable to the 1000 Genome Project (A-1572aT, G-1459aA, T-1017aC, T-129C, and A-43G), others were observed at frequencies two to eight times higher (A-684aT, G-274aA, and G-240A) or two to four times lower (T-1517aC, G-1157aA, A-41aG, and C133A).
Bayesian statistics implemented in PHASE were then used to infer the haplotypes encompassing these 12 Table 1 Single-nucleotide polymorphisms found in the promoter of ABCB1 in the 1000 Genome Project SNPs. PHASE analysis inferred 28 potential haplotypes of which 12 were found in our population with frequencies ranging from 0.5 to 88% (Table 2) . Two additional haplotypes that were not inferred by PHASE (haplotypes 29, 30; Table 2 ) were also found in the study population. The ancestral haplotype 1 (-1572aA/-1517aT/-1459aG/-1157aG/-1017aT/-684aA/-274aG/-41aA/-240G/-129T/-43A/133C) was the most common (frequency of 88%) and was considered the reference haplotype for subsequent promoter activity comparisons. Within the study population, there were six haplotypes which were found only one time with a minor allele frequency of 0.5%. The 14 haplotypes identified formed 12 paired haplotype combinations. We evaluated the effect of the 14 haplotypes found in our population on promoter activity, as well as two additional haplotypes that we generated (M1 and M4) to determine effects of individual SNPs found in specific haplotypes.
These SNPs were found in two haplotypes: one in haplotype 30 conferring decreased expression and the other in haplotype 29 conferring increased expression. Haplotype 30 is composed of two SNPs (G-1157aA; rs28381797 and T-1017aC; rs28746504). To determine the effect of each SNP individually on promoter activity, two constructs would have to be available, each containing one of these two SNPs. SNP T-1017aC is found individually as haplotype 9. To determine the effect of G-1157aA individually, we used site-directed mutagenesis to generate haplotype M4. Similarly, haplotype 29 is composed of two SNPs (G-1459aA; rs12720464 and T-129C; rs3213619). SNP G-1459aA is found individually as haplotype 16. To determine the effect of SNP T-129C individually, we created construct M1 using sitedirected mutagenesis.
Effect of different ABCB1 haplotypes on promoter activity
Each of the 16 haplotype sequences (14 observed in our population and two generated by site-directed mutagenesis) were ligated into pNL1.1 luciferase reporter plasmids. The luciferase reporter gene is driven by the inserted ABCB1 haplotype promoter, allowing the promoter activity to be determined from luciferase chemiluminescence. Promoter haplotype NanoLuc plasmids were cotransfected into placental 3A trophoblast cells with a firefly luciferase containing plasmid to control for transfection efficiency.
Using this assay system, we found significant haplotypedependent variations in luciferase activity. As shown in Fig. 1 , compared with the ancestral haplotype (haplotype 1), haplotype 30 showed a 94.4% decrease in promoter activity (P < 0.01), whereas haplotypes M4, 29, and 4 produced significant increases (P < 0.05) in promoter activity with 107.4, 247.4, and 290.2% increases, respectively. Other haplotypes evaluated showed differential effects on promoter activity, however the differences were not statistically significant.
Differential effects of single-nucleotide polymorphisms in the context of haplotypes
Our data indicate the effects from individual SNPs on promoter activity depends on their presence in a specific haplotype. For example, the T-1017aC SNP is found in several haplotypes. When this SNP is found with the variant G-1157aA (haplotype 30), the promoter activity was dramatically reduced (94% reduction; P < 0.01). However, when this variant is found individually (haplotype 9), an increase in promoter activity of 48.8% relative to haplotype 1 was observed (Fig. 1) . When the effect of the G-1157aA SNP alone was tested (haplotype M4), the promoter activity was significantly increased to 107.4% of haplotype 1 (P < 0.05).
The only haplotype containing the G-240A variant is haplotype 4. This haplotype exhibited a significant increase in activity (290%; P < 0.001). Thus, this increase could be attributed to this specific variant. Haplotype 29, associated with a significant 247% increase in promoter activity, is composed of the G-1459A and T-129C SNPs. When T-129C was found in conjunction with another SNP (as in haplotype 10), the promoter activity was not significantly affected (reduced by 9% compared with haplotype 1). However, when the T-129C SNP was tested alone using haplotype M1 generated by sitedirected mutagenesis, only a slight nonsignificant increase in activity (13% compared with haplotype 1) was observed. It seemed plausible to assume that the G-1459A variant is responsible for that dramatic increase observed with haplotype 29 on the basis of the T-129C data. However, when G-1459A is present alone (haplotype 16), a nonsignificant increase (∼12%) in activity was observed compared with haplotype 1.
Discussion
We determined the haplotype structure encompassing the SNPs present in the ABCB1 promoter region and investigated their effects on promoter activity. ABCB1 promoter haplotype structures have been previously described for a Japanese (n = 115) and a Caucasian (n = 96) population [16] . In this study, Takane et al. [16] described 10 SNPs/deletions in the ABCB1 promoter, identifying eight SNPs in Japanese and two additional SNPs in Caucasians. They reported the SNPs segregating into 10 haplotypes varying in frequency between Japanese and Caucasians.
In our investigation, we identified 12 SNPs but none of the reported insertions/deletions [16] . Moreover, we found 14 haplotypes of which three were reported by Takane et al. [16] : our haplotypes 1, 10 and 16. However, the frequencies of these haplotypes varied considerably. In our study, the frequency of haplotype 1 was 88.1% compared with 66.5 and 96.4% for Japanese and Caucasians Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
[16], respectively. Similarly, haplotype 10 was not found in the Japanese, but was found at a frequency of 1.6% in Caucasians [16] compared with 2.5% in our population. Haplotype 16 was found at a frequency of 19.1% in Japanese but was not found in Caucasians [16] and was 3.0% in our population. The discrepancy between our study and Takane et al. [16] could be attributed to the different racial/ethnic backgrounds and the number of individuals evaluated within each population (Supplementary Table S2 , Supplemental digital content 2, http://links.lww.com/FPC/B303). In our study, PHASE predicted 28 possible haplotypes in our population, however we only observed 12 in addition to two that were not predicted. This could be attributed to the relatively small number of patients we evaluated (n = 100).
Consistent with our previous studies [20, 27] , our data indicate that evaluation of SNPs in the context of haplotypes is more accurate to determine their functional and biological effects. A case in point is the G-1157aA, which when found in haplotype 30, it produced a significant decrease in promoter activity, however, when G-1157aA is found alone (haplotype M4), the activity was significantly increased, indicating that individual SNPs are not always the phenotype drivers. This corroborates our earlier observations involving the O-6-methylguanine DNA methyltransferase (MGMT) gene [20, 21] . In these studies, we found the MGMT promoter SNP C575A (rs113813075) may have no effect in one haplotype but can have dramatic effects on MGMT expression when found in another haplotype. Our data, therefore, provide explanations for discrepant results of studies evaluating effects of the same SNP. For example, when considering the pharmacogenomic effects of the coding ABCB1 SNP C3435T in the context of total body digoxin exposure, this SNP was reported to be associated with increased, decreased, and also with no effect on digoxin area under the curve (reviewed in the study by Pauli-Magnus and Kroetz [28] ). The differences observed could be due to the lack of consideration of ABCB1 promoter haplotypes in these studies which could potentially increase or decrease P-gp expression, thus masking the effect of the coding SNP evaluated.
Although there was some concordance between our study and Takane et al. [16] with respect to haplotypes structures, there were discrepancies in the biological effects observed. For example, although Takane et al. [16] reported a 30% increase with haplotype 10, we found no significant change in promoter activity. This could be attributed to several factors including experimental differences and host cells used for the expression assays. In their studies, Takane et al. [16] used HepG2 hepatoma cells for promoter expression assays, whereas we used 3A placental cells.
In fact, when we tested our same ABCB1 haplotype constructs in U87MG glioblastoma cells, we observed differences in the activity of some promoter haplotypes compared with those observed with the 3A trophoblasts (data not shown). Wang et al. [29] reported differences in promoter expression when evaluating ABCB1 promoter SNPs depending on cell lines used. Differences in expression in varying cell lines is not surprising and could be due to differences in TFs known to exist between cells [30] .
The mechanisms underlying the differential ABCB1 haplotype effects on promoter activity remains elusive. One mechanism may involve alterations in TF binding sites, resulting in differential TF binding and/or modification of cofactor recruitment [31] [32] [33] . In-silico analysis of the ABCB1 promoter predicted many putative binding sites for more than 80 TFs. Several putative sites are depicted in Fig. 2 . All SNPs identified in this study, with the exception of T-129C, were predicted to form or eliminate one or more putative TF binding site(s). Therefore, it is plausible to hypothesize that the observed expression changes are driven by SNPsinduced sequence alterations in close proximity or within TF binding motifs. Changes in these motifs may have different effects when SNPs are found together in specific haplotypes. Among the TFs binding sites predicted to be altered are GR-α, GR-β, C/EBP-β, AhR, GATA-1, NF-1, and several others (Supplementary  Table S3 , Supplemental digital content 3, http://links.lww. com/FPC/B304). Consistent with this hypothesis, changes in ABCB1 promoter activity was observed after introducing mutations in promoter Sp1 binding sites [36] . Importantly, one Sp1 binding domain was found to have a repressive role and alteration of this site led to higher promoter activity [36] . This region contains the G-240A SNP found in haplotype 4, which could affect the repressive Sp1 regulation, possibly explaining our observed significant increase in activity with this ABCB1 promoter haplotype luciferase activity. ABCB1 promoter haplotype nanoluciferase activity was measured and normalized in-well with firefly luciferase for each of the 14 haplotypes observed in the population as well as for the two haplotypes generated by site-directed mutagenesis. The resulting activity was normalized to the activity of the ancestral promoter haplotype (haplotype 1) for comparison. Data are presented as mean SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
haplotype. Alternatively, the G-240A variant could generate a higher affinity binding site for a transcription activator or alter the secondary structure of the DNA. Additional support to this hypothesis is provided by our previous work with MGMT [20, 21] . In these studies, we observed haplotype-dependent TF binding profiles that significantly correlated with MGMT promoter activity [21] .
Other possible mechanisms for the observed haplotypesdependent promoter activity could involve non-cis-acting mechanisms. For example, it has been reported that SNPs can alter methylation patterns within gene promoters [37] . Therefore, haplotypes could alter methylation patterns, especially when SNPs occur in CpG rich regions. For ABCB1, there are two to three CpG islands [34, 35] and variable interindividual levels of methylations have been observed [38] . Takane et al. [16] demonstrated that methylation pattern variability within the ABCB1 promoter led to differential expression of the gene. However, the effects of haplotypes on the ABCB1 promoter methylation pattern needs further investigation.
Another potential mechanism is allelic imbalance, which is a deviation from the expected equal expression from each individual allele. In studies addressing multiple genes, it was found that this ratio can deviate from the expected 1 : 1 up to 4.3 : 1 expression [39] . In studies specifically involving ABCB1, this phenomenon appears to favor the expression of an allele containing C3435T if present in the gene [40] . However, these studies evaluated only two SNPs in the distal promoter region and six tagging SNPs within the introns and exons but did not address the more commonly studied proximal ABCB1 promoter. ABCB1 proximal promoter sequence, single-nucleotide polymorphisms (SNPs) and transcription factor binding sites. The map shows the 2350 bp ABCB1 proximal promoter region sequenced in this study. The gray nucleotides represent the 12 SNPs identified in this study. Boxes represent some of the PROMO predicted transcription factor binding sites near SNPs. Underlined nucleotides represent CpG islands predicted by CpG Island Searcher [34] , whereas the italicized bases are CpG islands predicted by EMBL-EBI [35] . For SNP variants: R = A or G, Y = C or T, W = A or T, M = A or C.
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In summary, we provided a detailed haplotype structure for the ABCB1 promoter in a mixed ethnic/racial population. We demonstrated the effect of an individual SNP is not always consistent and differs in a haplotype-specific manner, indicating that ABCB1 haplotypes, rather than individual SNPs, affect its expression and could thus play a significant role in the expression of placental P-gp. Our study underscores the need for future mechanistic investigations elucidating the multiple cis-acting and trans-acting effects of promoter haplotypes to better understand how they affect promoter activity and subsequent protein expression.
